Clinical case series showed clinically meaningful reductions in wound size and pain, and improved tissue regranulation in chronic wound patients using revyve ® over 6–12 weeks Preclinical in vitro studies demonstrated >80% reduction in protease activity, including complete inhibition of TACE and collagenase — key factors in non-healing chronic wounds revyve ® data featured in presentations and posters at NSWOCC and SAWC—two... Read More

WINNIPEG, Manitoba, July 14, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane Biotech” or “Kane”) announces today that Kane Biotech’s Interim Chief Executive Officer, Dr. Robert Huizinga, will be presenting at the 4 th Advanced Wound Care Summit USA taking place from July 15-17, 2025 in Boston, MA. The Advanced Wound Care Summit USA is an industry gathering dedicated to the business of wound care where... Read More

WINNIPEG, Manitoba, June 26, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) announces that today it has completed its previously announced conversion (the “Transaction”) of an unsecured demand loan of $1 million from an insider of the Company into a $1 million principal amount 3% unsecured convertible debenture that is due on June 26, 2030 (the “Debenture”). For further details on... Read More

WINNIPEG, Manitoba, June 18, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) provides updates on its reorganizational phase. The Company has terminated its exclusive distribution agreement with ProgenaCare Global LLC (“ProgenaCare”) dated April 18, 2023 due to various material breaches by ProgenaCare of the agreement. Activities to resecure distribution for its products in the... Read More

WINNIPEG, Manitoba, May 29, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces its first quarter 2025 financial results. First Quarter 2025 Financial Highlights (Comparatives Exclude Discontinued STEM Animal Health “STEM” Operations): Total revenue for the three months ended March 31, 2025 was $412,513 compared to $51,886 in the three months ended March 31, 2024.... Read More

WINNIPEG, Manitoba, May 05, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “ Company ”, “ Kane ” or “ Kane Biotech ”) announces that today it has completed its previously announced non-brokered private placement offering (the “ Offering ”) of common shares of the Company (“ Shares ”). At the closing of the Offering, Kane issued 12,000,000 Shares at a price of $0.10 per Share for gross proceeds of... Read More

WINNIPEG, Manitoba, April 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announced its fourth quarter and full year 2024 financial results. Fourth Quarter 2024 Financial Highlights (Comparatives Exclude Discontinued STEM Animal Health “STEM” Operations): Total revenue for the three months ended December 31,2024 was $125,859 compared to $57,788 in the... Read More

WINNIPEG, Manitoba,, April 11, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (“Kane Biotech” or the “Company”) announces today that it has terminated the previously announced service agreement dated January 17, 2025 (the “Previous OTBC Service Agreement”) with independent marketing firm Outside the Box Capital Inc. (“OTBC”) and entered into a new service agreement dated April 11, 2025 (the “New OTBC... Read More

WINNIPEG, Manitoba, March 13, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) ("Kane Biotech" or "Kane") announces today that it has received approval from the Internal Review Board (“IRB”) of the University of Miami Health System (“UHealth”) to commence a clinical study of Kane’s prototype DispersinB ® Acne Cleanser for the treatment of mild to moderate cases of Acne Vulgaris. The title of the study is... Read More

WINNIPEG, Manitoba, March 11, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (“Kane Biotech”) announces that it has concluded a three-year distribution agreement with Best Buy Medical Canada for its revyve ™ Antimicrobial Wound Gel Product line. In November 2024, Kane Biotech received Health Canada approval for its revyve ™ Antimicrobial Wound Gel, marking a significant milestone for the company in... Read More

WINNIPEG, Manitoba, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “ Company ”, “ Kane ” or “ Kane Biotech ”) announces that today it has completed the second and final closing of its previously announced non-brokered private placement offering (the “ Offering ”) of common shares of the Company (“ Shares ”). At the second and final closing of the Offering, Kane issued 4,235,000 Shares at a... Read More

WINNIPEG, Manitoba, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc . (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday, January 23, 2025 at 4:15pm Eastern Time. Participants can register for the webinar by using this link: Kane Webinar – Jan 23, 2025 Marc Edwards, President and CEO, along with Dr. Robert Huizinga, Executive Chairman will update investors as to what they should... Read More

WINNIPEG, Manitoba, Jan. 20, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “ Company ”, “ Kane ” or “ Kane Biotech ”) announces that today it has completed the first closing of its previously announced non-brokered private placement offering (the “ Offering ”) of common shares of the Company (“ Shares ”). At the first closing Kane issued 12,750,000 Shares at a price of $0.10 per Share for aggregate... Read More

WINNIPEG, Manitoba, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it intends to undertake a non-brokered private placement offering of up to 30,000,000 common shares of the Company (each a “ Share ”) at a price of $0.10 per Share for aggregate proceeds of up to $3,000,000 (the “ Offering ”). The proceeds from the Offering will be used for... Read More

WINNIPEG, Manitoba, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc . (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announces its third quarter 2024 financial results. Third Quarter 2024 Financial Highlights (Comparatives Exclude Discontinued STEM Animal Health “STEM” Operations): Product sales for the three months ended September 30, 2024 was $597,677 compared to $3,631 in the three months... Read More

WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech” or “Kane”) announces today that BioStem Technologies Inc. (“BioStem”), has recently signed a Letter of Intent to acquire commercial stage products and development technologies from the Company’s current U.S. distributor, ProgenaCare Global LLC (“ProgenaCare”), including exclusive US distribution... Read More

WINNIPEG, Manitoba, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc . (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will release its third quarter 2024 financial results after market close on Thursday, November 28, 2024. Kane Biotech management will host a conference call at 4:30 p.m. ET on December 3, 2024 to review the financial results and discuss business developments in the period. Participants must register for the... Read More

WINNIPEG, Manitoba, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its revyve™ Antimicrobial Wound Gel as a Class 2 Medical Device. This approval allows the Company to immediately start promoting and selling this product in Canada. “We are excited to bring this much needed product to Canada,” said... Read More

WINNIPEG, Manitoba, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech”) announces today that President & CEO, Marc Edwards and Dr. Robert Huizinga, Executive Chair of Kane Biotech have released a video outlining the details and benefits to Kane Biotech and its investors of the FB Dermatology S.R.L. (“FB Dermatology”) transaction which the Company announced on November... Read More

WINNIPEG, Manitoba, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “ Company ”, “ Kane Biotech ”) announces today that it has entered into a binding term sheet (the “ Term Sheet ”) setting out the key terms and conditions relating to the acquisition of all of the issued and outstanding shares (the “ Purchased Shares ”) of FB Dermatology S.R.L. (“ FB Dermatology ”), incorporated under the... Read More

WINNIPEG, Manitoba, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it is donating 2,000 ounces of revyve™ Antimicrobial Wound Gel to the Ukraine medical relief effort. The product will be used to assist in the healing of severe and chronic wounds that tens of thousands of Ukrainian casualties have suffered as a result of the devasting effects of war. “I... Read More

WINNIPEG, Manitoba, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has signed an exclusive five year distribution agreement with XSONX LLC (“XSONX”) for Kane to distribute XSONX’s Wound Hygiene System in Canada, Australia, New Zealand and the Gulf Cooperation Council (GCC) Countries (the “Territories”). The XSONX Wound Hygiene System is a cordless... Read More

WINNIPEG, Manitoba, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that it is receiving advisory services and up to $75,000 in funding through the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to collaborate on a research and development project with a multinational corporate partner. The goal of the... Read More

WINNIPEG, Manitoba, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the Company will be showcasing its revyve™ Antimicrobial Wound Gel and revyve™ Antimicrobial Wound Gel Spray products at the following wound care conferences: Symposium on Advanced Wound Care (SAWC) (October 2-5, 2024 in Las Vegas Nevada) where Kane will be presenting... Read More

WINNIPEG, Manitoba, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces the exercise of an aggregate of 5 million warrants at an exercise price of $0.10 per common share for total proceeds of $500,000. “The shares are being held by some long-term supporters of Kane,” said Marc Edwards, President & CEO. The proceeds from these warrant exercises will be used for... Read More

WINNIPEG, Manitoba, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announces its second quarter 2024 financial results. The second quarter 2024 financial results reflect the closing of the sale of STEM which took place on April 12, 2024. The Company recorded a gain of $10,359,882 on this transaction which is offset by income tax loss carry... Read More

WINNIPEG, Manitoba, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc . (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces the publication of a new review article on DispersinB ® in the journal Pathogens . Pathogens is an international, peer-reviewed, open access journal focusing on pathogens and pathogen-host interactions. The article, entitled “Aggregatibacter actinomycetemcomitans Dispersin B: The... Read More

WINNIPEG, Manitoba, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has signed a three year distribution agreement with Qatar Datamation Systems (“QDS”) for its revyve™ Antimicrobial Wound Gel in the Qatar wound care market. “Kane continues its global commercialization of revyve™ with its second distribution agreement in the Middle East,”... Read More

WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will announce its second quarter 2024 financial results after market close on Thursday, August 29, 2024. Kane Biotech management will host a conference call at 4:30 p.m. ET on August 29, 2024 to review the financial results and discuss business developments in the period. Participants must register for the call... Read More

WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has signed a three year distribution agreement with Razan Medical & Surgical Equipment Trading LLC (“Razan Medical” or “Razan Medical Trading”) for its revyve™ Antimicrobial Wound Gel in the United Arab Emirates (UAE) wound care market. “At Razan Medical, we are dedicated... Read More

WINNIPEG, Manitoba, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that it is receiving advisory services and up to $200,000 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”). The funding will be received over a period of 20 months and will support the... Read More

WINNIPEG, Manitoba, July 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the US Food and Drug Administration (FDA) has eliminated its usage limitation on the Company’s 510(k) cleared revyve™ Antimicrobial Wound Gel (“revyve™”). Prior to the removal of this restriction, there was a 90 grams/month limit to the amount of revyve™ product that could... Read More

WINNIPEG, Manitoba, July 17, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has received ISO 13485:2016 Medical Device Single Audit Program (“MDSAP”) Quality Certification as a designer, developer and manufacturer of medical devices. This achievement speaks to Kane’s demonstrated commitment to bringing quality products to market. These standards require the... Read More

WINNIPEG, Manitoba, July 15, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has issued 4,213,133 restricted share units of the Company (“RSUs”) to various directors, officers, employees and consultants of the Company pursuant to the third amended and restated performance and restricted share unit plan of the Company dated May 22, 2024 (the “PRSU... Read More

WINNIPEG, Manitoba, July 11, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has signed a worldwide license agreement with Arizona-based Omni Bioceutical Innovations Inc. (“Omni”) for its coactiv+™ line of scalp care products. The five-year non-exclusive agreement will see Omni commercialize Kane’s scalp detoxifier product under the Omni Bioceuticals brand in... Read More

WINNIPEG, Manitoba, June 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has made its first commercial-scale sale of revyve™ Antimicrobial Wound Gel product (“revyve™”) to ProgenaCare Global LLC (“ProgenaCare”). Kane has now completely fulfilled its obligation related to the USD$500,000 initial manufacturing scale up fee received upon signing an exclusive... Read More

WINNIPEG, Manitoba, June 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has entered into a worldwide license agreement with I-MED Pharma Inc. (“I-MED Pharma” or “I-MED”) for the DispersinB ® technology. Biofilm is a known contributor to Meibomian gland dysfunction (MGD) and dry eye blepharitis syndrome (DEBS). The DispersinB ® enzyme will be used to... Read More

WINNIPEG, Manitoba, May 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its first quarter 2024 financial results. The Company previously announced on April 11, 2024 that it had reached an agreement in principle for the sale of its entire interest in STEM Animal Health Inc. (“STEM”) to a third party multi-national pharmaceutical company on a cash-free... Read More

WINNIPEG, Manitoba, May 16, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will release its first quarter 2024 financial results after market close on Thursday, May 23, 2024. Kane Biotech management will be... Read More

WINNIPEG, Manitoba, May 15, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces its intent to commercialize the patented assay which is to be named the Schultz Biofilm Wound Map in honour of the late Dr. Greg Schultz, former Professor Emeritus at the University of Florida and Chief Science Officer of Kane. The Schultz Biofilm Wound Map is the first and only... Read More

WINNIPEG, Manitoba, April 16, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane”) announces that it will be hosting a webinar on Thursday April 18th, 2024 at 4:15pm Eastern Time. Marc Edwards, Kane's President & CEO, will share his thoughts on what the sale of STEM Animal Health, which should ultimately net Kane more than $13 million CND, means for Kane as an important step in becoming a market... Read More

WINNIPEG, Manitoba, April 15, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“ Kane ”) announces that, it has completed the sale of its interest in STEM Animal Health Inc. to Dechra Veterinary Products, Inc. for US $8,000,000, plus net cash held in STEM (estimated at CND $600,000) and a working capital adjustment (estimated at CND $350,000) (the “ Transaction ”). Overall, it is anticipated that the... Read More

WINNIPEG, Manitoba, April 11, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “ Company ” or “ Kane Biotech ”) announces today that it has reached an agreement in principle for the sale of its entire interest (the “ Interest ”) in STEM Animal Health Inc. (“ STEM ”) to a third party multi-national pharmaceutical company (the “ Purchaser ”) on a cash-free debt-free basis for US $8,000,000 (the “... Read More

WINNIPEG, Manitoba, March 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces its fourth quarter and full year 2023 financial results. On December 20, 2023, Kane Biotech announced that it received a non-binding offer for its interest in STEM Animal Health. The terms of the offer remain confidential but specify that Kane will sell its ownership of STEM. In... Read More

WINNIPEG, Manitoba, March 20, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), announces today that it has extended the exclusivity period on the offer for its interest in STEM Animal Health that it announced on December 20, 2023, from March 19, 2024 until March 31, 2024. Kane further announces that subsequent to the US $625,000 deposit that it received at the time of... Read More

WINNIPEG, Manitoba, March 19, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its fourth quarter and full year 2023 financial results after market close on Tuesday, March 26, 2024. Kane Biotech... Read More

WINNIPEG, Manitoba, March 08, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the Bioscience Association of Manitoba (“BAM”) annual awards dinner held on March 7, 2024, Kane Biotech received the BAM Company of the Year award. Marc Edwards, President & CEO, accepted the award on behalf of the Company. “We’re very honoured to be the recipient of... Read More

WINNIPEG, Manitoba, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that at the special meeting of the shareholders of the Company held on February 20, 2024, Dr. Robert Huizinga was elected as a director of the Company. Mr. Huizinga has also been appointed by the directors of the Company as Executive Chair of the Company. In this new role in... Read More

WINNIPEG, Manitoba, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) announces that it has filed a patent on its revyve™ Antimicrobial Wound Gel Spray, a follow-on product to its FDA 510(k) cleared revyve™ Antimicrobial Wound Gel, and will be introducing it today at the Boswick Burn and Wound Care Symposium. “Kane has taken their revyve™ Antimicrobial... Read More

WINNIPEG, Manitoba, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) today announces that the Company will be presenting its revyve™ Antimicrobial Wound Gel at the Boswick Burn and Wound Care Symposium. The international conference will take place from January 27 to February 1, 2024 in Maui, Hawaii and covers the latest advancements in wound healing, burn... Read More

WINNIPEG, Manitoba, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on February 20, 2024, the Company will hold a special meeting of its shareholders (the “Meeting”) to consider the election of Dr. Robert Huizinga as an additional director of the Company. The information circular and other materials with respect to the Meeting will be... Read More

WINNIPEG, Manitoba, Dec. 29, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) today announces a correction to its press release dated December 28, 2023. The maturity date of the Company’s amended and restated credit facility between Pivot I Financial Limited Partnership and the Company dated August 31, 2021, as amended, has been extended to March 31, 2024, not March... Read More

WINNIPEG, Manitoba, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on December 20, 2023, the Company and Pivot I Financial Limited Partnership (“Pivot”) entered into a definitive agreement to amend the terms of the Company’s amended and restated credit facility between Pivot and the Company dated August 31, 2021, as amended (the... Read More

WINNIPEG, Manitoba, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces today that on December 19, 2023, it signed a non-binding offer for the sale of its interest in STEM Animal Health Inc. (“STEM”). “In 2018, when I joined as CEO, Kane made the strategic decision to continue to build Kane’s animal health portfolio, while expanding into advanced... Read More

WINNIPEG, Manitoba, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its third quarter 2023 financial results. Third Quarter Financial Highlights: Revenue from product and services for the three months ended September 30, 2023 was $548,785 an increase of 29% from $425,671 in the three months ended September 30, 2022. This increase is due mainly to... Read More

WINNIPEG, Manitoba, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its third quarter 2023 financial results after market close on Tuesday, November 28, 2023. Kane Biotech management will host... Read More

WINNIPEG, Manitoba, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) is pleased to announce that John Coleman has been appointed to the Board of Directors of Kane Biotech effective immediately. Dr. Coleman brings a wealth of scientific and business expertise to the board. Currently serving as the President and CEO of Avivo Biomedical Inc., a... Read More

WINNIPEG, Manitoba, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) in partnership with ProgenaCare Global LLP (“ProgenaCare”) today announces the launch of the newly rebranded revyve™ Antimicrobial Wound Gel (formerly coactiv+™ Antimicrobial Wound Gel). “We are... Read More

WINNIPEG, Manitoba, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it will be unveiling the new brand for its coactiv+™ Antimicrobial Wound Gel product (“Wound Gel”) at the Symposium on Advanced Wound Care Fall forum (“SAWC Fall”). Both Kane Biotech and its U.S. Wound Gel distribution partner, ProgenaCare Global, will host informational... Read More

WINNIPEG, Manitoba, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “ Company ”, “ Kane ” or “ Kane Biotech ”) announces that on September 11, 2023 it has fully subscribed and closed its previously announced non-brokered private placement offering (the “ Offering ”) of units of the Company (“ Units ”). Kane issued 6,250,000 Units at a price of $0.08 per Unit for aggregate gross proceeds of... Read More

68% Increase in Product and Services Revenue; 74% Increase in Royalties Revenue WINNIPEG, Manitoba, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its second quarter 2023 financial results. Second Quarter Financial Highlights: Revenue from product and services for the three months ended June 30, 2023 was $484,433 an increase of 68% from $287,584... Read More

WINNIPEG, Manitoba, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its second quarter 2023 financial results after market close on Tuesday, August 29, 2023. Kane Biotech management will host a... Read More

WINNIPEG, Manitoba, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “ Company ”, “ Kane ” or “ Kane Biotech ”) today announces its intention to undertake a non-brokered private placement offering (the “ Offering ”) of up to 6,250,000 units of the Company (“ Units ”) at a price of $0.08 per Unit for gross proceeds of up to $500,000. Each Unit shall be comprised of one common share of the... Read More

WINNIPEG, Manitoba, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “ Company ”, “ Kane ” or “ Kane Biotech ”) announced today that it has engaged Research Capital Corporation as Kane’s exclusive financial advisor (the “ Advisor ”) to conduct a strategic review process for its STEM Animal Health business division (“ STEM ”). Kane is considering a variety of strategic alternatives to maximize... Read More

WINNIPEG, Manitoba, June 23, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF), (the “Company” or “Kane Biotech”), today announces that it has issued 9,703,809 restricted share units of the Company (“RSUs”) to various directors, officers, employees and consultants of the Company pursuant to the second amended and restated performance and restricted share unit plan of the Company dated May 23, 2023. Each RSU... Read More

WINNIPEG, Manitoba, May 25, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced its first quarter 2023 financial results. First Quarter Financial Highlights: Total revenue for the three months ended March... Read More

WINNIPEG, Manitoba, May 25, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that on May 24, 2023 it received 510(k) clearance of its coactiv+ ™ Antimicrobial Wound Gel from the U.S. Food and Drug Administration (FDA) for the management of ulcers (including diabetic... Read More

WINNIPEG, Manitoba, May 18, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its first quarter 2023 financial results after market close on Thursday, May 25, 2023. Kane Biotech management will host a... Read More

WINNIPEG, Manitoba, April 20, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), today announced its fourth quarter and full year 2022 financial results. Fourth Quarter Financial Highlights Total revenue for the three months ended December 31, 2022 was $691,654, an increase of 68% compared to $411,693 for the three months ended December 31, 2021. This increase is primarily... Read More

WINNIPEG, Manitoba, April 20, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announced today that it has signed a distribution agreement with ProgenaCare Global LLC (“ProgenaCare”) for its coactiv+™ Antimicrobial Wound Gel in the United States wound care market. ProgenaCare will have exclusive distribution rights in the United States wound care market for Kane’s... Read More

WINNIPEG, Manitoba, April 18, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces that it has signed a licensing agreement with Skout’s Honor Pet Supply Company (“Skout’s Honor”) for its patented coactiv+™ technology in pet oral care applications. Skout’s Honor has been granted a ten-year license for the non-exclusive use of Kane’s coactiv+™ technology under... Read More

WINNIPEG, Manitoba, April 13, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. ( TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its fourth quarter and full year 2022 financial results after market close on Thursday, April 20, 2023. Kane Biotech... Read More

WINNIPEG, Manitoba, March 03, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that, as previously announced by the Company in its March 1, 2023 press release, pursuant to the formal amending agreement (the “Amending Agreement”) with Pivot Financial I Limited Partnership (“Pivot”) dated March 2, 2023 amending the terms of the Company’s amended and restated... Read More

WINNIPEG, Manitoba, March 02, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced that it has entered into a formal amending agreement (the “Amending Agreement”) with Pivot Financial I Limited Partnership (“Pivot”), to amend the terms of the Company’s amended and restated credit agreement between Pivot and the Company dated August 31, 2021, as amended (the... Read More

WINNIPEG, Manitoba, March 01, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced that Pivot Financial I Limited Partnership (“Pivot”) has agreed, in principle, to amend the terms of the Company’s amended and restated credit agreement between Pivot and the Company dated August 31, 2021, as amended (the “Credit Facility”), by, among other things, increasing the... Read More

WINNIPEG, Manitoba, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company” or “Kane Biotech”) announces today that it has entered into an amending agreement with Pivot Financial I Limited Partnership (“Pivot”) to the amended and restated credit agreement between the Company and Pivot dated August 31, 2021, extending the maturity date of its credit facility from January 31, 2023 to February 28, 2023.... Read More

WINNIPEG, Manitoba, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces today that it has recently signed a distribution agreement with Salud Pharma S.A. (“Salud Pharma”) for its coactiv+™ Antimicrobial Hydrogel wound care and DermaKB™ scalp care products. Once Kane obtains 510(k) approval from the FDA, Salud Pharma through its distribution partners will... Read More

WINNIPEG, Manitoba, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has reached an agreement to obtain loans (the “Loans”) in the aggregate amount of $2,000,000 from two lenders (the “Lenders”). The Loans will bear interest at 12% per annum and mature on March 31, 2024. As partial consideration for providing the Loans, the Lenders will be... Read More